Department of Medical Oncology, Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA, USA.
Med Oncol. 2010 Jun;27 Suppl 1:S1-6. doi: 10.1007/s12032-010-9442-2. Epub 2010 Feb 19.
Multiple myeloma is a clonal B-cell malignancy characterized by aberrant expression of plasma cells within the bone marrow, and is associated with the well known clinical manifestations anemia, bone disease, renal dysfunction, hypercalcemia, and recurrent infections. For many years, melphalan and prednisone represented the standard of care in multiple myeloma therapy, with stem cell transplantation reserved for selected patients. Treatment of the disease has evolved rapidly over the past decade, however, with the development and utilization of thalidomide, lenalidomide, and bortezomib. As a result of these developments, clinical outcomes have improved significantly. This review highlights important historic landmarks as well as more recent events that have played an important role in the evolution of myeloma therapy.
多发性骨髓瘤是一种克隆性 B 细胞恶性肿瘤，其特征是骨髓中浆细胞异常表达，并伴有众所周知的临床表现，如贫血、骨病、肾功能不全、高钙血症和反复感染。多年来，美法仑和泼尼松一直是多发性骨髓瘤治疗的标准方案，而干细胞移植则保留给选定的患者。然而，在过去十年中，随着沙利度胺、来那度胺和硼替佐米的开发和应用，该疾病的治疗迅速发展。由于这些进展，临床结果得到了显著改善。这篇综述强调了在骨髓瘤治疗演变中发挥重要作用的重要历史里程碑和最近的事件。
